BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. NKE
8. MU
9. PFE
10. AWK

Go back to BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years

Piper Sandler Reiterates Overweight Rating on BioCryst Pharma (BCRX)

February 24, 2025 1:18 PM EST

Piper Sandler analyst Tyler Van Buren reiterated an Overweight rating and $23.00 price target on BioCryst Pharma (NASDAQ: BCRX)

The analyst comments "Remain OW rated on BCRX shares after a solid Q424 Orladeyo print, reporting $124.2M versus the $123.5M preliminary revenue pre-released last month.... More

JPMorgan Reiterates Overweight Rating on BioCryst Pharma (BCRX)

February 24, 2025 8:58 AM EST

JPMorgan analyst Jessica Fye reiterated an Overweight rating and $10.00 price target on BioCryst Pharma (NASDAQ: BCRX)

The analyst comments "We think the ~3% upward guidance revision to FY25 Orladeyo revs by ~$18mm at the midpoint to $535-$550mm (vs prior guidance of $515-$535mm established earlier this year at our healthcare conference) will be well received as it supports 24% growth YoY for Orladeyo at the midpoint after 34% Orladeyo growth in 24. Well listen... More